|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
|
US6120794A
(en)
*
|
1995-09-26 |
2000-09-19 |
University Of Pittsburgh |
Emulsion and micellar formulations for the delivery of biologically active substances to cells
|
|
WO2001008708A2
(en)
*
|
1999-07-29 |
2001-02-08 |
Case Western Reserve University |
Enhanced delivery via serpin enzyme complex receptor ligands
|
|
US6387700B1
(en)
|
1996-11-04 |
2002-05-14 |
The Reagents Of The University Of Michigan |
Cationic peptides, Cys-Trp-(LYS)n, for gene delivery
|
|
US6913926B2
(en)
*
|
1996-11-21 |
2005-07-05 |
Cedars-Sinai Medical Center |
Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2
|
|
US6894031B1
(en)
*
|
1996-11-21 |
2005-05-17 |
Cedars-Sinai Medical Center |
Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
|
|
US7097829B2
(en)
*
|
1996-11-21 |
2006-08-29 |
Cedars-Sinai Medical Center |
Transgenic cells transfected with pituitary tumor transforming gene (PTTG)) expression vectors and uses therefor
|
|
AU3758199A
(en)
*
|
1998-04-23 |
1999-11-08 |
Regents Of The University Of Michigan, The |
Peptides for efficient gene transfer
|
|
US6903077B1
(en)
|
1999-01-04 |
2005-06-07 |
University Of Vermont And State Agricultural College |
Methods and products for delivering nucleic acids
|
|
US6770740B1
(en)
|
1999-07-13 |
2004-08-03 |
The Regents Of The University Of Michigan |
Crosslinked DNA condensate compositions and gene delivery methods
|
|
JP4813720B2
(ja)
*
|
1999-11-08 |
2011-11-09 |
イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ヒト循環ウイルス阻害ペプチド（ｖｉｒｉｐ）及びその使用
|
|
US7355019B2
(en)
*
|
2000-06-06 |
2008-04-08 |
Sibtech, Inc. |
Cysteine-containing peptide tag for site-specific conjugation of proteins
|
|
EP1170373A1
(en)
*
|
2000-07-03 |
2002-01-09 |
Retina France |
Peptide-mediated ocular cell transfection
|
|
US20020182626A1
(en)
*
|
2001-03-16 |
2002-12-05 |
Daniel Tuse |
Episomal non-transforming nucleic acid elements in functional genomic and antigenic applications
|
|
CA2445947A1
(en)
*
|
2001-04-30 |
2002-11-07 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
|
US6909030B2
(en)
|
2001-10-15 |
2005-06-21 |
Cedars-Sinai Medical Center |
PTTG knockout rodent as a model to study mechanisms for various physiological phenomena, including diabetes
|
|
AU2003256329A1
(en)
*
|
2002-06-27 |
2004-01-19 |
University Of Washington |
Use of adhesion molecules as bond stress-enhanced nanoscale binding switches
|
|
US20040016013A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
|
|
US20040014698A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
|
US20040014704A1
(en)
*
|
2002-07-18 |
2004-01-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent induces tolerance
|
|
JP2004179274A
(ja)
*
|
2002-11-26 |
2004-06-24 |
Hitachi Ltd |
光半導体装置
|
|
ATE519782T1
(de)
*
|
2002-12-19 |
2011-08-15 |
Ipf Pharmaceuticals Gmbh |
Peptide und ihre verwendung zur behandlung von hiv infektionen
|
|
US20050136437A1
(en)
*
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
|
US20050208032A1
(en)
*
|
2004-01-16 |
2005-09-22 |
Gonzalo Hortelano |
Oral administration of therapeutic agent coupled to transporting agent
|
|
ES2503739T3
(es)
|
2004-11-12 |
2014-10-07 |
Asuragen, Inc. |
Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
|
|
DE102005005528A1
(de)
*
|
2005-01-30 |
2006-08-03 |
Eberhard-Karls-Universität Tübingen Universitätsklinikum |
Injizierbares Mittel zur zielgerichteten Behandlung von retinalen Ganglienzellen
|
|
WO2007127219A2
(en)
*
|
2006-04-25 |
2007-11-08 |
Immune Disease Institute, Inc. |
Targeted delivery to leukocytes using protein carriers
|
|
EP2434017A3
(en)
|
2006-08-01 |
2012-09-05 |
Board of Regents of the University of Texas System |
Identification of a micro-RNA that activates expression of beta-myosin heavy chain
|
|
BRPI0719912A2
(pt)
|
2006-12-06 |
2014-03-04 |
Medimmune Llc |
Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico
|
|
AU2008247395A1
(en)
|
2007-05-03 |
2008-11-13 |
Medimmune, Llc |
Auto-antibody markers of autoimmune disease
|
|
NZ583024A
(en)
|
2007-07-31 |
2012-04-27 |
Regents The Univeristy Of Texas System Board Of |
An agonist of miR-29a, miR-29b or miR-29c that prevents tissue fibrosis and uses thereof
|
|
ES2667729T3
(es)
|
2007-09-26 |
2018-05-14 |
Ucb Biopharma Sprl |
Fusiones de anticuerpos con doble especificidad
|
|
US8202848B2
(en)
|
2008-03-17 |
2012-06-19 |
Board Of Regents, The University Of Texas System |
Identification of micro-RNAS involved in neuromuscular synapse maintenance and regeneration
|
|
HUE033438T2
(en)
*
|
2008-09-26 |
2017-11-28 |
Ucb Biopharma Sprl |
Biological products
|
|
EP2379720B1
(en)
|
2009-01-20 |
2016-08-17 |
Alona Zilberberg |
Mir-21 promoter driven targeted cancer therapy
|
|
NZ595471A
(en)
|
2009-04-14 |
2014-01-31 |
Nestec Sa |
Inflammatory bowel disease prognostics
|
|
WO2011030107A1
(en)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Multivalent antibodies
|
|
CA2780741C
(en)
|
2009-10-12 |
2023-04-04 |
Smith Holdings, Llc |
Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
|
|
WO2011060098A1
(en)
|
2009-11-10 |
2011-05-19 |
Prometheus Laboratories Inc. |
Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
|
|
EP2542678B1
(en)
|
2010-03-04 |
2017-04-12 |
InteRNA Technologies B.V. |
A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS THERAPEUTIC USES IN CANCER ASSOCIATED WITH EMT
|
|
NZ605420A
(en)
|
2010-07-06 |
2015-02-27 |
Interna Technologies Bv |
Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
|
|
WO2012067837A1
(en)
*
|
2010-11-15 |
2012-05-24 |
Avon Products, Inc. |
Biofunctional anchored extended-wear cosmetics
|
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
|
JP2015502740A
(ja)
|
2011-10-21 |
2015-01-29 |
ネステク ソシエテ アノニム |
炎症性腸疾患の診断を改善するための方法
|
|
EP3369818B1
(en)
|
2011-12-22 |
2021-06-09 |
InteRNA Technologies B.V. |
Mirna for treating head and neck cancer
|
|
EP2822600A4
(en)
|
2012-03-09 |
2016-04-06 |
Univ Northeastern |
METHOD OF DISTRIBUTING NUCLEIC ACID ANOPARTICLES TO THE CENTRAL NERVOUS SYSTEM FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
|
|
EP3800256A1
(en)
|
2012-11-06 |
2021-04-07 |
InteRNA Technologies B.V. |
Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway
|
|
AU2013361077A1
(en)
|
2012-12-21 |
2015-07-09 |
The Trustees Of Columbia University In The City Of New York |
Biomarkers for chronic traumatic encephalopathy
|
|
WO2014151551A1
(en)
|
2013-03-15 |
2014-09-25 |
Baylor Research Institute |
Ulcerative colitis (uc)-associated colorectal neoplasia markers
|
|
AU2014287063A1
(en)
|
2013-07-11 |
2016-01-28 |
The Trustees Of Columbia University In The City Of New York |
MicroRNAs that silence tau expression
|
|
US10172916B2
(en)
|
2013-11-15 |
2019-01-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
WO2015074010A2
(en)
|
2013-11-18 |
2015-05-21 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
|
EP2960252A1
(en)
*
|
2014-06-26 |
2015-12-30 |
Institut Pasteur |
Phospholipase for treatment of immunosuppression
|
|
NZ749593A
(en)
|
2016-06-20 |
2025-10-31 |
Univ Leland Stanford Junior |
Circular rnas and their use in immunomodulation
|
|
US11958911B2
(en)
*
|
2017-02-10 |
2024-04-16 |
Shanghai Benemae Pharmaceutical |
Anti-coagulation factor XI antibody
|
|
JP6784973B2
(ja)
*
|
2017-03-30 |
2020-11-18 |
国立研究開発法人産業技術総合研究所 |
単層カーボンナノチューブ
|
|
US11590202B2
(en)
|
2017-04-11 |
2023-02-28 |
University Of Maryland, Baltimore |
Inhibitors of LTβR-NFκB signaling pathways for treating inflammation and cancer
|
|
US12416015B2
(en)
|
2017-09-15 |
2025-09-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multiplex production and barcoding of genetically engineered cells
|
|
ES2897248T3
(es)
|
2017-10-03 |
2022-02-28 |
Aptahem Ab |
Molécula de ácido nucleico con propiedades antiinflamatorias, anticoagulantes y organoprotectoras
|
|
CA3079524A1
(en)
|
2017-11-03 |
2019-05-09 |
Interna Technologies B.V. |
Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
|
|
CN109836500A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
EP4419684A1
(en)
|
2021-10-21 |
2024-08-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Retroelement-generated transcription factor decoys
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4499839A1
(en)
|
2022-03-25 |
2025-02-05 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Methods of assessing engineered retron activity, and uses thereof
|
|
WO2023183589A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Rt-dna fidelity and retron genome editing
|
|
WO2023183627A1
(en)
|
2022-03-25 |
2023-09-28 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
|
|
US20250230429A1
(en)
|
2022-04-07 |
2025-07-17 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Continuous Multiplexed Phage Genome Engineering Using a Retron Editing Template
|
|
WO2024036232A2
(en)
*
|
2022-08-09 |
2024-02-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibodies and uses thereof
|
|
WO2024044673A1
(en)
|
2022-08-24 |
2024-02-29 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Dual cut retron editors for genomic insertions and deletions
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|